Targeting the Human β_c Receptor Inhibits Contact Dermatitis in a Transgenic Mouse Model.

Area of Science:

• Immunology
• Dermatology
• Transgenic animal models

Background:

• Allergic contact dermatitis (ACD) is a common inflammatory skin condition driven by T cells and granulocytes.
• Beta common (βc) cytokines like GM-CSF, IL-3, and IL-5 regulate granulocyte function and are implicated in ACD.
• Targeting the βc receptor is a strategy to inhibit these cytokines, but species specificity has limited in vivo studies.

Purpose of the Study:

• To develop a novel mouse model for studying human βc cytokine function in ACD.
• To investigate the specific roles of GM-CSF, IL-3, and IL-5 in ACD pathogenesis.
• To validate the efficacy of βc inhibitors in a relevant preclinical model.

Main Methods:

• Development of a human βc receptor transgenic mouse model with hematopoietic cell-specific expression.
• In vitro assessment of human βc receptor cell response to mouse GM-CSF, IL-3, and IL-5.
• Induction of ACD in transgenic and wild-type mice, followed by histological analysis and immune cell profiling.
• Treatment of ACD model with a blocking anti-human βc antibody (CSL311).

Main Results:

• Human βc receptor transgenic cells responded to mouse GM-CSF and IL-5, but not IL-3 in vitro.
• The transgenic mouse model recapitulated ACD pathology and inflammation seen in wild-type mice.
• Treatment with the anti-βc antibody CSL311 significantly reduced ACD severity, including skin thickening and immune cell infiltration (neutrophils, mast cells, eosinophils).

Conclusions:

• GM-CSF and IL-5 are the primary mediators of ACD, while IL-3 plays a minor role.
• The developed human βc receptor transgenic mouse is a valuable preclinical model for testing βc inhibitors in vivo.
• This study provides a platform for advancing therapeutic strategies targeting βc cytokines in allergic inflammatory diseases.